Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 26, 2021 13:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports 2020 Financial Results and Provides Business Update

Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer, OSE-127/S95011 in ulcerative colitis, FR104 in renal transplant and an upcoming phase 1/2...
March 15, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,...
March 11, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting

CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation.BiCKI®-IL-7, bifunctional therapy targeting PD-1 and IL-7 to...
February 23, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presentation at H.C. Wainwright Global Life Sciences Conference

NANTES, France, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of...
February 17, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011

NANTES, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that it has strengthened intellectual property rights for its...
February 15, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank

This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,Divided into three tranches including...
January 28, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development...
January 25, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

Milestone as part of the collaborative program named EFFIMab marks continued clinical progressInterleukin-7 receptor antagonist (IL-7R) OSE-127/S95011 is currently in a Phase 2 clinical trial in...
January 05, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference

NANTES, France, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of...
December 21, 2020 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011

NANTES, France, Dec. 21, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced enrolment of the first patient in its Phase 2 clinical trial evaluating the...